Investment analysts at Ascendiant Capital Markets initiated coverage on shares of Cyclo Therapeutics (NASDAQ:CYTH – Get Free Report) in a note issued to investors on Monday, Benzinga reports. The firm set a “buy” rating and a $2.60 price target on the stock. Ascendiant Capital Markets’ target price points to a potential upside of 114.88% from the stock’s current price.
Cyclo Therapeutics Trading Down 4.0 %
NASDAQ:CYTH opened at $1.21 on Monday. The firm has a 50-day moving average price of $1.50 and a two-hundred day moving average price of $1.46. Cyclo Therapeutics has a twelve month low of $0.68 and a twelve month high of $2.57. The company has a market capitalization of $34.75 million, a P/E ratio of -0.92 and a beta of -0.15.
Cyclo Therapeutics (NASDAQ:CYTH – Get Free Report) last released its quarterly earnings results on Monday, March 18th. The company reported ($0.23) earnings per share (EPS) for the quarter. Cyclo Therapeutics had a negative return on equity of 4,506.97% and a negative net margin of 1,864.03%. The firm had revenue of $0.31 million for the quarter.
Institutional Investors Weigh In On Cyclo Therapeutics
About Cyclo Therapeutics
Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.
See Also
- Five stocks we like better than Cyclo Therapeutics
- What is the S&P/TSX Index?
- Charles Schwab Fortifies its Uptrend on EPS Beat
- What Are Dividend Contenders? Investing in Dividend Contenders
- Lockheed Martin Stock Aims for a Fresh All-Time High
- Stock Analyst Ratings and Canadian Analyst Ratings
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for Cyclo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.